Literature DB >> 11731709

Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases.

Myron F Weiner1, Rachelle S Doody, Ramesh Sairam, Barbara Foster, Tso-yu Liao.   

Abstract

BACKGROUND: Reports on the frequency of major depression in Alzheimer's disease are conflicting, some suggesting that it is frequent, others suggesting that it is uncommon.
METHODS: We examined the prevalence and incidence of symptom clusters meeting criteria for major depressive disorder (MDD) in two large series of cases diagnosed prospectively by NINCDS/ADRDA criteria as probable or possible Alzheimer's disease. Standard DSM-III-R criteria were employed at one site, the CERAD modification of DSM-III-R criteria at the other. Both sites required the presence of depressed mood on direct patient examination at the time of initial evaluation in order to meet criteria for MDD.
RESULTS: At the center using standard DSM-III-R criteria (n = 329), there was a 0.9% prevalence of symptom clusters meeting criteria for MDD. At the center using the CERAD modification (n = 586), MDD prevalence was 4.8%. Incidence rates at both centers were below 2% per year over 3 years.
CONCLUSIONS: We concluded that DSM-III-R MDD is not common in AD patients. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11731709     DOI: 10.1159/000048627

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  9 in total

1.  Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study.

Authors:  C Arbus; V Gardette; C E Cantet; S Andrieu; F Nourhashémi; L Schmitt; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

2.  Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis.

Authors:  J K Kuring; J L Mathias; L Ward
Journal:  Neuropsychol Rev       Date:  2018-12-07       Impact factor: 7.444

3.  [Relation between certain diseases and frequency of depression in geriatric patients].

Authors:  V Zietemann; P Zietemann; R Weitkunat; A Kwetkat
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

4.  Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Authors:  Gerda G Fillenbaum; Gerald van Belle; John C Morris; Richard C Mohs; Suzanne S Mirra; Patricia C Davis; Pierre N Tariot; Jeremy M Silverman; Christopher M Clark; Kathleen A Welsh-Bohmer; Albert Heyman
Journal:  Alzheimers Dement       Date:  2008-03       Impact factor: 21.566

Review 5.  Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.

Authors:  Vasiliki Orgeta; Afifa Qazi; Aimee E Spector; Martin Orrell
Journal:  Cochrane Database Syst Rev       Date:  2014-01-22

Review 6.  Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis.

Authors:  Vasiliki Orgeta; Afifa Qazi; Aimee Spector; Martin Orrell
Journal:  Br J Psychiatry       Date:  2015-10       Impact factor: 9.319

7.  Incidence and Course of Depression in Patients with Alzheimer's Disease.

Authors:  Seung-Ho Ryu; Han-Yong Jung; Kang Joon Lee; Seok Woo Moon; Dong Woo Lee; Narei Hong; Baik Seok Kee; Do Hoon Kim; Changsu Han; Chang Uk Lee
Journal:  Psychiatry Investig       Date:  2017-05-16       Impact factor: 2.505

8.  IDEA intervention to prevent depressive symptoms and promote well-being in early-stage dementia: protocol for a randomised controlled feasibility study.

Authors:  Remco Tuijt; Gill Livingston; Rebecca L Gould; Rebecca Jones; Elisabet Sole Verdaguer; Vasiliki Orgeta
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

9.  Validation of geriatric depression and anxiety rating scales into Arabic.

Authors:  Georges Elie Karam; Mohannad Nawaf Khandakji; Nayri Sarkis Sahakian; Jessica Christian Dandan; Elie Georges Karam
Journal:  Alzheimers Dement (Amst)       Date:  2018-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.